Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Special target medicine and its use

A targeted and specific technology, applied in the direction of drug combination, application, antineoplastic drugs, etc., can solve the problems of not being able to effectively reduce the adverse reactions of IFN, and not being able to improve the curative effect of IFN at the dose

Active Publication Date: 2007-10-03
SHANGHAI HEP PHARMA
View PDF0 Cites 24 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, only prolonging the half-life of IFN in vivo (J.Pharmaceut.Sci., 83:601-606, 1994) by means of polyethylene glycol coupling, protein coupling, etc., although it can prolong the administration time interval and reduce the number of administrations, but It cannot effectively reduce the adverse reactions caused by IFN, nor can it improve the efficacy of IFN by increasing the dosage

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Special target medicine and its use
  • Special target medicine and its use
  • Special target medicine and its use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] Embodiment 1 Design of specific targeting interferon amino acid sequence

[0052] 1. The X sequence selects the 1st to 50th amino acid sequence (SEQ ID NO: 3) of the large surface protein of the HBV strain FMC#97, which includes the widely confirmed specific binding to the surface of liver cells and mediates HBV infection of liver cells. key sequence.

[0053] 2. L selects a sequence composed of flexible amino acids (SEQ ID NO: 4) to reduce the interaction between X and Y in terms of protein conformation and function.

[0054] 3. The Y sequence selects the full-length amino acid sequence of IFNα-2b (SEQ ID NO: 5).

[0055] 4. X and Y are respectively located at the N-terminus and C-terminus of the L sequence, and the overall sequence formed is shown in SEQ ID NO:6.

[0056] 5. Carry out glycosylation site analysis on SEQ ID NO: 6 (see Figure 1), wherein the 15th amino acid asparagine is a possible N-linked glycosylation modification site, which is subjected to similar...

Embodiment 2

[0057] The design of the DNA sequence of embodiment 2 coding specific targeting interferon

[0058] 1. Select Pichia pastoris as the expression system for specific targeting interferon. Pichia pastoris is the most successful eukaryotic expression system for exogenous protein expression (Cereghino J L, Cregg J M. Heterologous protein expression in the methylotrophic yeast Pichia pastoris [J]. FEMS MicrobiolRev, 2000, 24 (1): 45 -66.). It not only has the characteristics of rapid propagation, low cost and convenient operation of the prokaryotic expression system, but also has the advantages of the eukaryotic expression system with correct processing and folding of exogenous proteins and moderate glycosylation. Therefore, it is more and more widely used for the mass expression of proteins. At present, more than 200 kinds of proteins have been expressed in this expression system (Cregg JM, Cereghino JL, Shi JY, et al. Recombinant protein expression in Pichia pastoris[J].Mol Biot...

Embodiment 3

[0061] Embodiment 3 Construction of specific targeting interferon yeast expression vector

[0062] 1. Select pPIC9K as the yeast expression vector for specific targeting interferon. pPIC9K is a multi-copy secretory expression vector introduced by Invitrogen, with a size of 9.3kb (as shown in Figure 3A). The vector contains Escherichia coli replication origin Col E1 and two resistance genes of ampicillin and kanamycin, and the kanamycin resistance gene can also make Pichia pastoris resistant to G418, which can be used for screening of multiple copy insertions . The promoter of the alcohol oxidase gene (pAOX1) is used in the vector as an inducible promoter, which is inhibited by glucose and starts transcription and translation after being induced by methanol, which is very suitable for the expression of foreign genes. pPIC9K uses the secretion signal of a mating factor leader sequence to secrete the target gene product to the extracellular space. Since Pichia pastoris only se...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A specific target medicine, the nucleic acid sequence for coding it, the expression carrier containing said nucleic acid sequence, the host cell transformed from said carrier, and its application in preparing the medicines for treating hepatism, such as viral hepatitis, hepatocirrhosis and liver tumor, are disclosed.

Description

technical field [0001] The invention relates to a specific targeted drug, in particular to a specific targeted drug for treating liver diseases such as viral hepatitis, liver cirrhosis, and liver tumors. Background technique [0002] Specific selection of host cells by viruses is widespread in the phenomenon of viral infection. There is a class of viruses that can specifically or relatively specifically infect liver cells in nature, called hepatotropic viruses. Currently recognized human hepatotropic viruses are human hepatitis A, B, C, D, and E, "hepatitis G virus" and newly discovered transfusion-transmitted viruses TTV (including its mutant strains SANBAN, YONBAN, etc.), SENV ( TTV-related virus), TLMV (TTV-like parvovirus), and CAV (chicken leukemia virus) can cause hepatitis lesions, but they have not yet been recognized as hepatotropic viruses. In addition, the etiology of about 10% of viral hepatitis has not yet been determined clinically, which is called untyped he...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/16A61K38/18A61K38/21A61K47/48A61P1/16A61P31/14A61P31/20A61P35/00C12N15/11C12N15/12C12N15/63A61K47/64C12N1/19C12N1/21C12N5/10
CPCY02A50/30
Inventor 刘宏利
Owner SHANGHAI HEP PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com